Andrew Berens
Stock Analyst at Leerink Partners
(1.72)
# 3,346
Out of 5,050 analysts
98
Total ratings
47.67%
Success rate
-8.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $12.15 | +105.76% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $74.52 | -19.48% | 2 | Jul 28, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $16 → $18 | $14.82 | +21.46% | 5 | Jul 7, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $125 → $140 | $93.35 | +49.97% | 2 | Jun 24, 2025 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $6.89 | +117.71% | 1 | Oct 31, 2025 | |
| MRUS Merus | Downgrades: Market Perform | $95 → $97 | $95.23 | +1.86% | 6 | Oct 6, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $10.63 | -15.33% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $4.23 | +41.84% | 3 | Apr 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Market Perform | $880 → $762 | $657.53 | +15.89% | 1 | Jan 28, 2025 | |
| OKUR OnKure Therapeutics | Initiates: Outperform | $33 | $2.94 | +1,022.45% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $16.46 | +51.88% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $118.84 | -19.22% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $60 → $56 | $40.67 | +37.69% | 11 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $105.98 | -26.40% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $12.31 | +127.46% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $84.58 | -6.60% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.28 | +2,009.38% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $7.19 | +247.71% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $5.35 | +647.66% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.34 | +2,763.25% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $12.31 | +62.47% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $7.87 | +217.66% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $10.85 | -26.27% | 7 | Jul 14, 2017 |
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $12.15
Upside: +105.76%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $74.52
Upside: -19.48%
Cogent Biosciences
Jul 7, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $14.82
Upside: +21.46%
Nuvalent
Jun 24, 2025
Maintains: Outperform
Price Target: $125 → $140
Current: $93.35
Upside: +49.97%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $6.89
Upside: +117.71%
Merus
Oct 6, 2025
Downgrades: Market Perform
Price Target: $95 → $97
Current: $95.23
Upside: +1.86%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $10.63
Upside: -15.33%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $4.23
Upside: +41.84%
Regeneron Pharmaceuticals
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $657.53
Upside: +15.89%
OnKure Therapeutics
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.94
Upside: +1,022.45%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $16.46
Upside: +51.88%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $118.84
Upside: -19.22%
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $40.67
Upside: +37.69%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $105.98
Upside: -26.40%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $12.31
Upside: +127.46%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $84.58
Upside: -6.60%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.28
Upside: +2,009.38%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $7.19
Upside: +247.71%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $5.35
Upside: +647.66%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.34
Upside: +2,763.25%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $12.31
Upside: +62.47%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $7.87
Upside: +217.66%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $10.85
Upside: -26.27%